Clinical Phenotypes And Survival Of Idiopathic Pulmonary Fibrosis In One Group Of Patients In Brazil

Rufino, Rogério; Silva, Vinicius Lemos da; Bártholo, Thiago Prudente; Pugliese, José Gustavo; Costa, Cláudia Henrique da

doi:10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1542

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of COPD (including emphysema) was reported in 23 studies (online supplementary table S1), of which eight were from Europe [18][19][20][21][22][23][24][25], eight were from North America [6,[26][27][28][29][30][31][32], six were from Asia [33][34][35][36][37][38] and one was from South America (Brazil) [39]. The reported prevalence of COPD ranged from 6% to 67% (figure 2) ( prevalence ranges by country: 12% [21] to 51% [18] in Europe, 8% [26] to 67% [31] in North America and 34% [36] to 65% [34] in Asia).…”

Section: Respiratory Comorbidities Copdmentioning

confidence: 99%

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

et al. 2015

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities. The prevalence and impact of comorbidities on the clinical course of IPF is unclear.This systematic literature review examined the prevalence of comorbidities and mortality associated with comorbidities in IPF patients. Relevant observational studies published in English from January 1990 to January 2015 identified via MEDLINE and EMBASE were included; bibliographies of articles were also searched.Among the 126 studies included, prevalence of pulmonary hypertension (PH) was 3-86%, 6-91% for obstructive sleep apnoea, 3-48% for lung cancer and 6-67% for chronic obstructive pulmonary disease (COPD). Nonrespiratory comorbidities included ischaemic heart disease (IHD) (3-68%) and gastrooesophageal reflux (GER) (0-94%). Mortality was highest among patients with IPF and lung cancer. Most studies assessed relatively small samples of patients with IPF.PH, COPD, lung cancer, GER and IHD are significant comorbidities; differences in IPF severity, case definitions and patient characteristics limited the comparability of findings. The identification and prompt treatment of comorbidities may have a clinically significant impact on overall outcome that is meaningful for patients with IPF. @ERSpublications Identification and prompt treatment of comorbidities has a clinically significant impact on outcome for IPF patients

show abstract